
|Videos|October 3, 2020
HER2-targeted Therapy: Routes of Administration
Author(s)Staff
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Advertisement
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC
2
Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML
3
Pembrolizumab Plus RT Ups T-Cell Infiltration in Early Breast Cancer
4
Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma
5
















































































